MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2018 International Congress

    It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

    M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

    Objective: This study determined the efficacy of internally guided (leading) versus externally guided (following) in adapted tango versus a contact-matched control group (wellness education) for…
  • 2018 International Congress

    Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

    Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…
  • 2018 International Congress

    Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

    V. Kumar (Allahabad, India)

    Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…
  • 2018 International Congress

    A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease

    H. Huttunen, S. Booms, J. Koskinen, M. Saarma (Espoo, Finland)

    Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…
  • 2018 International Congress

    Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

    P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

    Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…
  • 2018 International Congress

    Motivators, Barriers and Clinical Correlates of Physical Activity in Parkinson Disease

    S. Mantri, S. Wood, J. Duda, J. Morley (Philadelphia, PA, USA)

    Objective: To characterize physical activity levels as well as barriers and motivators for exercise in US military Veterans with Parkinson disease (PD). Background: Physical activity…
  • 2018 International Congress

    Nurr1 gene: A new research target for Parkinson’s disease

    W. Le (Dalian, China)

    Objective: The objective of our study is to determine if Nurr1 gene, a transcription factor essential for dopamine (DA) neuron development and survival, is a…
  • 2018 International Congress

    T lymphocytes in Parkinson’s disease pathogenesis and therapy: A systematic review

    J. Baird, J. Quinn (Portland, OR, USA)

    Objective: A systematic literature review was conducted to synthesize the current state of knowledge on the role of T lymphocytes in Parkinson’s disease (PD) pathology…
  • 2018 International Congress

    Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

    P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

    Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…
  • 2018 International Congress

    Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity

    G. Ho, T. Imberdis, S. Nuber, U. Dettmer, D. Selkoe (Boston, MA, USA)

    Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley